{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:05:38Z","timestamp":1792649138821,"version":"4.5.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40259-020-00453-8","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T09:02:49Z","timestamp":1604307769000},"page":"763-781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration"],"prefix":"10.1007","volume":"34","author":[{"given":"Paula I.","family":"Fuller-Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Basiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-5778","authenticated-orcid":false,"given":"Livia S.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"453_CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.visres.2017.05.009","volume":"139","author":"M Diaz-Coranguez","year":"2017","unstructured":"Diaz-Coranguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: cellular basis and development. Vis Res. 2017;139:123\u201337.","journal-title":"Vis Res"},{"issue":"11","key":"453_CR2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.gt.3302030","volume":"10","author":"J Bennett","year":"2003","unstructured":"Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther. 2003;10(11):977\u201382.","journal-title":"Gene Ther"},{"issue":"2","key":"453_CR3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/156652311794940746","volume":"11","author":"M Hellstrom","year":"2011","unstructured":"Hellstrom M, Harvey AR. Retinal ganglion cell gene therapy and visual system repair. Curr Gene Ther. 2011;11(2):116\u201331.","journal-title":"Curr Gene Ther"},{"key":"453_CR4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnins.2017.00174","volume":"11","author":"GA Ochakovski","year":"2017","unstructured":"Ochakovski GA, Bartz-Schmidt KU, Fischer MD. Retinal gene therapy: surgical vector delivery in the translation to clinical trials. Front Neurosci. 2017;11:174.","journal-title":"Front Neurosci"},{"key":"453_CR5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3389\/fphar.2019.01076","volume":"10","author":"JK Jolly","year":"2019","unstructured":"Jolly JK, Bridge H, MacLaren RE. Outcome measures used in ocular gene therapy trials: a scoping review of current practice. Front Pharmacol. 2019;10:1076.","journal-title":"Front Pharmacol"},{"issue":"2","key":"453_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/dbio.1998.9031","volume":"207","author":"M Hu","year":"1999","unstructured":"Hu M, Easter SS. Retinal neurogenesis: the formation of the initial central patch of postmitotic cells. Dev Biol. 1999;207(2):309\u201321.","journal-title":"Dev Biol"},{"issue":"3","key":"453_CR7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.visres.2007.07.027","volume":"48","author":"EM Surace","year":"2008","unstructured":"Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vis Res. 2008;48(3):353\u20139.","journal-title":"Vis Res"},{"issue":"5","key":"453_CR8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358\u201378.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"453_CR9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28(3):723\u201346.","journal-title":"Mol Ther"},{"issue":"4","key":"453_CR10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/gt.2008.178","volume":"16","author":"M Hellstrom","year":"2009","unstructured":"Hellstrom M, et al. Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Ther. 2009;16(4):521\u201332.","journal-title":"Gene Ther"},{"issue":"4","key":"453_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/hgtb.2016.054","volume":"27","author":"C Ling","year":"2016","unstructured":"Ling C, et al. Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses. Hum Gene Ther Methods. 2016;27(4):143\u20139.","journal-title":"Hum Gene Ther Methods"},{"issue":"5","key":"453_CR12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/hmg\/5.5.591","volume":"5","author":"RR Ali","year":"1996","unstructured":"Ali RR, et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet. 1996;5(5):591\u20134.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"453_CR13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/hum.2005.16.401","volume":"16","author":"TR Flotte","year":"2005","unstructured":"Flotte TR, Berns KI. Adeno-associated virus: a ubiquitous commensal of mammals. Hum Gene Ther. 2005;16(4):401\u20137.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"453_CR14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1165\/ajrcmb.11.5.7946381","volume":"11","author":"TR Flotte","year":"1994","unstructured":"Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol. 1994;11(5):517\u201321.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3685","key":"453_CR15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","volume":"149","author":"RW Atchison","year":"1965","unstructured":"Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. 1965;149(3685):754\u20136.","journal-title":"Science"},{"key":"453_CR16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coviro.2014.07.008","volume":"8","author":"E Zinn","year":"2014","unstructured":"Zinn E, Vandenberghe LH. Adeno-associated virus: fit to serve. Curr Opin Virol. 2014;8:90\u20137.","journal-title":"Curr Opin Virol"},{"issue":"4","key":"453_CR17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255\u201372.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"453_CR18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;101(5):839\u201362.","journal-title":"Neuron"},{"key":"453_CR19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-neuro-080317-062048","volume":"41","author":"CN Bedbrook","year":"2018","unstructured":"Bedbrook CN, Deverman BE, Gradinaru V. Viral strategies for targeting the central and peripheral nervous systems. Annu Rev Neurosci. 2018;41:323\u201348.","journal-title":"Annu Rev Neurosci"},{"issue":"17","key":"453_CR20","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.96.17.9920","volume":"96","author":"J Bennett","year":"1999","unstructured":"Bennett J, et al. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci USA. 1999;96(17):9920\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"453_CR21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nm0696-649","volume":"2","author":"J Bennett","year":"1996","unstructured":"Bennett J, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med. 1996;2(6):649\u201354.","journal-title":"Nat Med"},{"issue":"7","key":"453_CR22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.gt.3300440","volume":"4","author":"C Jomary","year":"1997","unstructured":"Jomary C, et al. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther. 1997;4(7):683\u201390.","journal-title":"Gene Ther"},{"issue":"1","key":"453_CR23","first-page":"92","volume":"28","author":"GM Acland","year":"2001","unstructured":"Acland GM, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28(1):92\u20135.","journal-title":"Nat Genet"},{"issue":"4","key":"453_CR24","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1167\/iovs.02-0595","volume":"44","author":"K Narfstrom","year":"2003","unstructured":"Narfstrom K, et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Investig Ophthalmol Vis Sci. 2003;44(4):1663\u201372.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"453_CR25","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ymthe.2005.08.008","volume":"12","author":"GM Acland","year":"2005","unstructured":"Acland GM, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005;12(6):1072\u201382.","journal-title":"Mol Ther"},{"issue":"3","key":"453_CR26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","volume":"59","author":"K Erles","year":"1999","unstructured":"Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999;59(3):406\u201311.","journal-title":"J Med Virol"},{"issue":"2","key":"453_CR27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1046-2023(02)00220-7","volume":"28","author":"S Zolotukhin","year":"2002","unstructured":"Zolotukhin S, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods. 2002;28(2):158\u201367.","journal-title":"Methods"},{"issue":"2","key":"453_CR28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","volume":"76","author":"JE Rabinowitz","year":"2002","unstructured":"Rabinowitz JE, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002;76(2):791\u2013801.","journal-title":"J Virol"},{"issue":"3","key":"453_CR29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","volume":"5","author":"G Gao","year":"2005","unstructured":"Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5(3):285\u201397.","journal-title":"Curr Gene Ther"},{"key":"453_CR30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fnins.2017.00503","volume":"11","author":"LS Carvalho","year":"2017","unstructured":"Carvalho LS, et al. Evaluating efficiencies of dual AAV approaches for retinal targeting. Front Neurosci. 2017;11:503.","journal-title":"Front Neurosci"},{"issue":"2","key":"453_CR31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","volume":"26","author":"A Maddalena","year":"2018","unstructured":"Maddalena A, et al. Triple vectors expand AAV transfer capacity in the retina. Mol Ther. 2018;26(2):524\u201341.","journal-title":"Mol Ther"},{"key":"453_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.preteyeres.2018.08.003","volume":"68","author":"JH Lee","year":"2019","unstructured":"Lee JH, et al. Gene therapy for visual loss: opportunities and concerns. Prog Retin Eye Res. 2019;68:31\u201353.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"453_CR33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/02713683.2019.1663385","volume":"45","author":"TZ Khatib","year":"2020","unstructured":"Khatib TZ, Martin KR. Neuroprotection in glaucoma: towards clinical trials and precision medicine. Curr Eye Res. 2020;45(3):327\u201338.","journal-title":"Curr Eye Res"},{"issue":"4","key":"453_CR34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.7.4.6","volume":"7","author":"JL Duncan","year":"2018","unstructured":"Duncan JL, et al. Inherited retinal degenerations: current landscape and knowledge gaps. Transl Vis Sci Technol. 2018;7(4):6.","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"453_CR35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","volume":"29","author":"W Berger","year":"2010","unstructured":"Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010;29(5):335\u201375.","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"453_CR36","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/IAE.0000000000002125","volume":"39","author":"M Talib","year":"2019","unstructured":"Talib M, et al. Clinical and genetic characteristics of male patients with RPGR-associated retinal dystrophies: a long-term follow-up study. Retina. 2019;39(6):1186\u201399.","journal-title":"Retina"},{"issue":"Pt B","key":"453_CR37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.visres.2014.07.013","volume":"111","author":"LS Carvalho","year":"2015","unstructured":"Carvalho LS, Vandenberghe LH. Promising and delivering gene therapies for vision loss. Vis Res. 2015;111(Pt B):124\u201333.","journal-title":"Vis Res"},{"issue":"13","key":"453_CR38","first-page":"2857","volume":"38","author":"J Bennett","year":"1997","unstructured":"Bennett J, et al. Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Investig Ophthalmol Vis Sci. 1997;38(13):2857\u201363.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"453_CR39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1089\/10430349950018715","volume":"10","author":"F Rolling","year":"1999","unstructured":"Rolling F, et al. Evaluation of adeno-associated virus-mediated gene transfer into the rat retina by clinical fluorescence photography. Hum Gene Ther. 1999;10(4):641\u20138.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"453_CR40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/77068","volume":"25","author":"RR Ali","year":"2000","unstructured":"Ali RR, et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet. 2000;25(3):306\u201310.","journal-title":"Nat Genet"},{"issue":"12","key":"453_CR41","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","volume":"17","author":"D Dalkara","year":"2009","unstructured":"Dalkara D, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther. 2009;17(12):2096\u2013102.","journal-title":"Mol Ther"},{"issue":"1","key":"453_CR42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/mcne.2002.1168","volume":"21","author":"AR Harvey","year":"2002","unstructured":"Harvey AR, et al. Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: a comparison with lentiviral vectors. Mol Cell Neurosci. 2002;21(1):141\u201357.","journal-title":"Mol Cell Neurosci"},{"issue":"5","key":"453_CR43","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1167\/iovs.10-6250","volume":"52","author":"L Yin","year":"2011","unstructured":"Yin L, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Investig Ophthalmol Vis Sci. 2011;52(5):2775\u201383.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"453_CR44","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1038\/s41598-018-23836-y","volume":"8","author":"H Yu","year":"2018","unstructured":"Yu H, et al. Longterm reversal of severe visual loss by mitochondrial gene transfer in a mouse model of Leber hereditary optic neuropathy. Sci Rep. 2018;8(1):5587.","journal-title":"Sci Rep"},{"issue":"21","key":"453_CR45","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","volume":"358","author":"JW Bainbridge","year":"2008","unstructured":"Bainbridge JW, et al. Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis. N Engl J Med. 2008;358(21):2231\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"453_CR46","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","volume":"19","author":"WW Hauswirth","year":"2008","unstructured":"Hauswirth WW, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19(10):979\u201390.","journal-title":"Hum Gene Ther"},{"issue":"21","key":"453_CR47","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, et al. Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med. 2008;358(21):2240\u20138.","journal-title":"N Engl J Med"},{"issue":"39","key":"453_CR48","doi-asserted-by":"crossref","first-page":"15112","DOI":"10.1073\/pnas.0807027105","volume":"105","author":"AV Cideciyan","year":"2008","unstructured":"Cideciyan AV, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA. 2008;105(39):15112\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"453_CR49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-0-387-74904-4_15","volume":"613","author":"K Narfstrom","year":"2008","unstructured":"Narfstrom K, et al. Morphological aspects related to long-term functional improvement of the retina in the 4\u00a0years following rAAV-mediated gene transfer in the RPE65 null mutation dog. Adv Exp Med Biol. 2008;613:139\u201346.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"453_CR50","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1089\/hum.2009.086","volume":"20","author":"AV Cideciyan","year":"2009","unstructured":"Cideciyan AV, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009;20(9):999\u20131004.","journal-title":"Hum Gene Ther"},{"issue":"9701","key":"453_CR51","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire AM, et al. Age-dependent effects of RPE65 gene therapy for Lebers congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374(9701):1597\u2013605.","journal-title":"Lancet"},{"issue":"3","key":"453_CR52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","volume":"18","author":"F Simonelli","year":"2010","unstructured":"Simonelli F, et al. Gene therapy for Leber\u2019s congenital amaurosis is safe and effective through 1.5\u00a0years after vector administration. Mol Ther. 2010;18(3):643\u201350.","journal-title":"Mol Ther"},{"issue":"1","key":"453_CR53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","volume":"130","author":"SG Jacobson","year":"2012","unstructured":"Jacobson SG, et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9\u201324.","journal-title":"Arch Ophthalmol"},{"issue":"120","key":"453_CR54","doi-asserted-by":"crossref","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","volume":"4","author":"J Bennett","year":"2012","unstructured":"Bennett J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4(120):120ra15.","journal-title":"Sci Transl Med"},{"issue":"6","key":"453_CR55","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","volume":"110","author":"AV Cideciyan","year":"2013","unstructured":"Cideciyan AV, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA. 2013;110(6):E517\u201325.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"453_CR56","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","volume":"120","author":"F Testa","year":"2013","unstructured":"Testa F, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013;120(6):1283\u201391.","journal-title":"Ophthalmology"},{"issue":"20","key":"453_CR57","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JW Bainbridge","year":"2015","unstructured":"Bainbridge JW, et al. Long-term effect of gene therapy on Leber\u2019s congenital amaurosis. N Engl J Med. 2015;372(20):1887\u201397.","journal-title":"N Engl J Med"},{"issue":"9","key":"453_CR58","doi-asserted-by":"crossref","first-page":"a017285","DOI":"10.1101\/cshperspect.a017285","volume":"5","author":"EA Pierce","year":"2015","unstructured":"Pierce EA, Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med. 2015;5(9):a017285.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10045","key":"453_CR59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388(10045):661\u201372.","journal-title":"Lancet"},{"issue":"7","key":"453_CR60","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","volume":"123","author":"RG Weleber","year":"2016","unstructured":"Weleber RG, et al. Results at 2\u00a0years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology. 2016;123(7):1606\u201320.","journal-title":"Ophthalmology"},{"key":"453_CR61","doi-asserted-by":"crossref","unstructured":"Le Meur, G., et al., Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis. Mol Ther. 2017.","DOI":"10.1016\/j.ymthe.2017.09.014"},{"issue":"10097","key":"453_CR62","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849\u201360.","journal-title":"Lancet"},{"issue":"4","key":"453_CR63","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/3813","volume":"20","author":"TM Redmond","year":"1998","unstructured":"Redmond TM, et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet. 1998;20(4):344\u201351.","journal-title":"Nat Genet"},{"issue":"38","key":"453_CR64","doi-asserted-by":"crossref","first-page":"13658","DOI":"10.1073\/pnas.0504167102","volume":"102","author":"TM Redmond","year":"2005","unstructured":"Redmond TM, et al. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci USA. 2005;102(38):13658\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"453_CR65","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/sj.mt.6300389","volume":"16","author":"J Bennicelli","year":"2008","unstructured":"Bennicelli J, et al. Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther J Am Soc Gene Ther. 2008;16(3):458\u201365.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"10\u201312","key":"453_CR66","first-page":"497","volume":"161","author":"F Rolling","year":"2006","unstructured":"Rolling F, et al. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Bull Mem Acad R Med Belg. 2006;161(10\u201312):497\u2013508 (discussion 508\u20139).","journal-title":"Bull Mem Acad R Med Belg"},{"issue":"4","key":"453_CR67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3302861","volume":"14","author":"G Le Meur","year":"2007","unstructured":"Le Meur G, et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 2007;14(4):292\u2013303.","journal-title":"Gene Ther"},{"issue":"2","key":"453_CR68","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1525-0016(03)00144-8","volume":"8","author":"AJ Smith","year":"2003","unstructured":"Smith AJ, et al. AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther. 2003;8(2):188\u201395.","journal-title":"Mol Ther"},{"issue":"20","key":"453_CR69","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","volume":"372","author":"SG Jacobson","year":"2015","unstructured":"Jacobson SG, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1920\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"453_CR70","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1089\/hum.2018.014","volume":"29","author":"ME Pennesi","year":"2018","unstructured":"Pennesi ME, et al. Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy. Hum Gene Ther. 2018;29(12):1428\u201337.","journal-title":"Hum Gene Ther"},{"issue":"12","key":"453_CR71","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1089\/hum.2010.047","volume":"21","author":"E Banin","year":"2010","unstructured":"Banin E, et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther. 2010;21(12):1749\u201357.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"453_CR72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-020-1304-1","volume":"15","author":"X Wang","year":"2020","unstructured":"Wang X, et al. The effect of human gene therapy for RPE65-associated Leber\u2019s congenital amaurosis on visual function: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):49.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"453_CR73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","volume":"135","author":"NG Ghazi","year":"2016","unstructured":"Ghazi NG, et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet. 2016;135(3):327\u201343.","journal-title":"Hum Genet"},{"key":"453_CR74","doi-asserted-by":"crossref","unstructured":"Ashtari M et al. Plasticity of the human visual system after retinal gene therapy in patients with Leber\u2019s congenital amaurosis. Sci Transl Med 2015;7(296):296ra110.","DOI":"10.1126\/scitranslmed.aaa8791"},{"issue":"9","key":"453_CR75","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy. Ophthalmology. 2019;126(9):1273\u201385.","journal-title":"Ophthalmology"},{"issue":"10","key":"453_CR76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/bjo.36.10.547","volume":"36","author":"A Sorsby","year":"1952","unstructured":"Sorsby A, et al. Choroideremia; clinical and genetic aspects. Br J Ophthalmol. 1952;36(10):547\u201381.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"453_CR77","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.ophtha.2016.06.051","volume":"123","author":"KN Khan","year":"2016","unstructured":"Khan KN, et al. Clinical and genetic features of choroideremia in childhood. Ophthalmology. 2016;123(10):2158\u201365.","journal-title":"Ophthalmology"},{"key":"453_CR78","doi-asserted-by":"crossref","unstructured":"Moosajee M et al. Clinical utility gene card for: choroideremia. Eur J Hum Genet. 2014;22(4).","DOI":"10.1038\/ejhg.2013.183"},{"issue":"2","key":"453_CR79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ng0592-109","volume":"1","author":"EM Sankila","year":"1992","unstructured":"Sankila EM, et al. Aberrant splicing of the CHM gene is a significant cause of choroideremia. Nat Genet. 1992;1(2):109\u201313.","journal-title":"Nat Genet"},{"issue":"2","key":"453_CR80","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13816810490514333","volume":"25","author":"M Preising","year":"2004","unstructured":"Preising M, Ayuso C. Rab escort protein 1 (REP1) in intracellular traffic: a functional and pathophysiological overview. Ophthal Genet. 2004;25(2):101\u201310.","journal-title":"Ophthal Genet"},{"issue":"11","key":"453_CR81","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1073\/pnas.0605818104","volume":"104","author":"BL Krock","year":"2007","unstructured":"Krock BL, Bilotta J, Perkins BD. Noncell-autonomous photoreceptor degeneration in a zebrafish model of choroideremia. Proc Natl Acad Sci USA. 2007;104(11):4600\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"453_CR82","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1167\/iovs.13-13454","volume":"55","author":"JI Morgan","year":"2014","unstructured":"Morgan JI, et al. High-resolution adaptive optics retinal imaging of cellular structure in choroideremia. Investig Ophthalmol Vis Sci. 2014;55(10):6381\u201397.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"2","key":"453_CR83","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI26617","volume":"116","author":"T Tolmachova","year":"2006","unstructured":"Tolmachova T, et al. Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia. J Clin Investig. 2006;116(2):386\u201394.","journal-title":"J Clin Investig"},{"issue":"6294","key":"453_CR84","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/347674a0","volume":"347","author":"FP Cremers","year":"1990","unstructured":"Cremers FP, et al. Cloning of a gene that is rearranged in patients with choroideraemia. Nature. 1990;347(6294):674\u20137.","journal-title":"Nature"},{"issue":"9923","key":"453_CR85","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren RE, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet. 2014;383(9923):1129\u201337.","journal-title":"Lancet"},{"issue":"20","key":"453_CR86","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMc1509501","volume":"374","author":"TL Edwards","year":"2016","unstructured":"Edwards TL, et al. Visual acuity after retinal gene therapy for choroideremia. N Engl J Med. 2016;374(20):1996\u20138.","journal-title":"N Engl J Med"},{"issue":"10","key":"453_CR87","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","volume":"24","author":"K Xue","year":"2018","unstructured":"Xue K, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med. 2018;24(10):1507\u201312.","journal-title":"Nat Med"},{"issue":"1","key":"453_CR88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/IAE.0000000000002360","volume":"40","author":"MD Fischer","year":"2020","unstructured":"Fischer MD, et al. Changes in retinal sensitivity after gene therapy in choroideremia. Retina. 2020;40(1):160\u20138.","journal-title":"Retina"},{"key":"453_CR89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","volume":"197","author":"BL Lam","year":"2019","unstructured":"Lam BL, et al. Choroideremia gene therapy phase 2 clinical trial: 24-month results. Am J Ophthalmol. 2019;197:65\u201373.","journal-title":"Am J Ophthalmol"},{"key":"453_CR90","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","volume":"193","author":"IS Dimopoulos","year":"2018","unstructured":"Dimopoulos IS, et al. Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience. Am J Ophthalmol. 2018;193:130\u201342.","journal-title":"Am J Ophthalmol"},{"key":"453_CR91","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1089\/10430349950016942","volume":"10","author":"JE Loeb","year":"1999","unstructured":"Loeb JE, et al. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther. 1999;10:2295\u2013305.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"453_CR92","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41431-018-0235-y","volume":"27","author":"N Jurkute","year":"2019","unstructured":"Jurkute N, et al. Clinical utility gene card for: inherited optic neuropathies including next-generation sequencing-based approaches. Eur J Hum Genet. 2019;27(3):494\u2013502.","journal-title":"Eur J Hum Genet"},{"issue":"4884","key":"453_CR93","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.3201231","volume":"242","author":"DC Wallace","year":"1988","unstructured":"Wallace DC, et al. Mitochondrial DNA mutation associated with Leber\u2019s hereditary optic neuropathy. Science. 1988;242(4884):1427\u201330.","journal-title":"Science"},{"issue":"112","key":"453_CR94","first-page":"112","volume":"3","author":"LH Vandenberghe","year":"2011","unstructured":"Vandenberghe LH, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Trans Med. 2011;3(112):112\u20139.","journal-title":"Sci Trans Med"},{"issue":"8","key":"453_CR95","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1089\/hum.2016.085","volume":"27","author":"SE Boye","year":"2016","unstructured":"Boye SE, et al. Highly efficient delivery of adeno-associated viral vectors to the primate retina. Hum Gen Ther. 2016;27(8):580\u201397.","journal-title":"Hum Gen Ther"},{"issue":"1","key":"453_CR96","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ymthe.2016.10.008","volume":"25","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, et al. Improved intravitreal AAV-mediated inner retinal gene transduction after surgical internal limiting membrane peeling in cynomolgus monkeys. Mol Ther. 2017;25(1):296\u2013302.","journal-title":"Mol Ther"},{"issue":"3","key":"453_CR97","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1089\/hgtb.2016.034","volume":"27","author":"T Kizito-Tshitoko","year":"2016","unstructured":"Kizito-Tshitoko T, et al. Vitrectomy before intravitreal injection of AAV2\/2 vector promotes efficient transduction of retinal ganglion cells in dogs and nonhuman primates. Hum Gen Ther Methods. 2016;27(3):122\u201334.","journal-title":"Hum Gen Ther Methods"},{"key":"453_CR98","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omtm.2018.12.006","volume":"13","author":"H Song","year":"2019","unstructured":"Song H, et al. Trans-ocular electric current in vivo enhances AAV-mediated retinal gene transduction after intravitreal vector administration. Mol Ther Methods Clin Dev. 2019;13:77\u201385.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"453_CR99","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ana.10354","volume":"52","author":"J Guy","year":"2002","unstructured":"Guy J, et al. Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy. Ann Neurol. 2002;52(5):534\u201342.","journal-title":"Ann Neurol"},{"key":"453_CR100","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/mtm.2015.3","volume":"2","author":"H Cwerman-Thibault","year":"2015","unstructured":"Cwerman-Thibault H, et al. Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss. Mol Ther Methods Clin Dev. 2015;2:15003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"453_CR101","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, et al. Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy. EBioMedicine. 2016;10:258\u201368.","journal-title":"EBioMedicine"},{"issue":"6","key":"453_CR102","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","volume":"125","author":"C Vignal","year":"2018","unstructured":"Vignal C, et al. Safety of rAAV2\/2-ND4 gene therapy for Leber hereditary optic neuropathy. Ophthalmology. 2018;125(6):945\u20137.","journal-title":"Ophthalmology"},{"issue":"2","key":"453_CR103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1566523219666190618094505","volume":"19","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, et al. Three cases of Leber\u2019s hereditary optic neuropathy with rapid increase in visual acuity after gene therapy. Curr Gene Ther. 2019;19(2):134\u20138.","journal-title":"Curr Gene Ther"},{"issue":"4","key":"453_CR104","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","volume":"137","author":"C Bouquet","year":"2019","unstructured":"Bouquet C, et al. Immune response and intraocular inflammation in patients with Leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1\/2 clinical trial. JAMA Ophthalmol. 2019;137(4):399\u2013406.","journal-title":"JAMA Ophthalmol"},{"key":"453_CR105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/104303401300042500","volume":"12","author":"L Xu","year":"2001","unstructured":"Xu L, et al. CMV-\u03b2-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1\u03b1 promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther. 2001;12:563\u201373.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"453_CR106","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jgm.516","volume":"6","author":"AR Brooks","year":"2004","unstructured":"Brooks AR, et al. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med. 2004;6(4):395\u2013404.","journal-title":"J Gene Med"},{"key":"453_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-0169-1","author":"B Nieuwenhuis","year":"2020","unstructured":"Nieuwenhuis B, et al. Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters. Gene Ther. 2020. https:\/\/doi.org\/10.1038\/s41434-020-0169-1.","journal-title":"Gene Ther"},{"key":"453_CR108","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/sj.gt.3301221","volume":"7","author":"JC Paterna","year":"2000","unstructured":"Paterna JC, et al. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther. 2000;7:1304\u201311.","journal-title":"Gene Ther"},{"issue":"2","key":"453_CR109","doi-asserted-by":"crossref","first-page":"e31061","DOI":"10.1371\/journal.pone.0031061","volume":"7","author":"J Rodger","year":"2012","unstructured":"Rodger J, et al. Long-term gene therapy causes transgene-specific changes in the morphology of regenerating retinal ganglion cells. PLoS ONE. 2012;7(2):e31061.","journal-title":"PLoS ONE"},{"key":"453_CR110","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/mtm.2016.78","volume":"3","author":"CJ LeVaillant","year":"2016","unstructured":"LeVaillant CJ, et al. Significant changes in endogenous retinal gene expression assessed 1\u00a0year after a single intraocular injection of AAV-CNTF or AAV-BDNF. Mol Ther Methods Clin Dev. 2016;3:16078.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"22","key":"453_CR111","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","volume":"105","author":"L Zhong","year":"2008","unstructured":"Zhong L, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA. 2008;105(22):7827\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"453_CR112","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/mt.2010.234","volume":"19","author":"H Petrs-Silva","year":"2011","unstructured":"Petrs-Silva H, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther. 2011;19(2):293\u2013301.","journal-title":"Mol Ther"},{"key":"453_CR113","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3389\/fnins.2017.00521","volume":"11","author":"KS Hanlon","year":"2017","unstructured":"Hanlon KS, et al. A novel retinal ganglion cell promoter for utility in AAV vectors. Front Neurosci. 2017;11:521.","journal-title":"Front Neurosci"},{"issue":"3","key":"453_CR114","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","volume":"123","author":"WJ Feuer","year":"2016","unstructured":"Feuer WJ, et al. Gene therapy for Leber hereditary optic neuropathy: initial results. Ophthalmology. 2016;123(3):558\u201370.","journal-title":"Ophthalmology"},{"issue":"11","key":"453_CR115","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"J Guy","year":"2017","unstructured":"Guy J, et al. Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results. Ophthalmology. 2017;124(11):1621\u201334.","journal-title":"Ophthalmology"},{"issue":"1","key":"453_CR116","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/JVI.72.1.309-319.1998","volume":"72","author":"EA Rutledge","year":"1998","unstructured":"Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol. 1998;72(1):309\u201319.","journal-title":"J Virol"},{"issue":"26","key":"453_CR117","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","volume":"10","author":"A Auricchio","year":"2001","unstructured":"Auricchio A, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet. 2001;10(26):3075\u201381.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"453_CR118","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1525-0016(03)00098-4","volume":"7","author":"M Weber","year":"2003","unstructured":"Weber M, et al. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther. 2003;7(6):774\u201381.","journal-title":"Mol Ther"},{"issue":"5","key":"453_CR119","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ymthe.2005.12.001","volume":"13","author":"K Stieger","year":"2006","unstructured":"Stieger K, et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther. 2006;13(5):967\u201375.","journal-title":"Mol Ther"},{"issue":"6","key":"453_CR120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41434-018-0031-x","volume":"25","author":"A Georgiadis","year":"2018","unstructured":"Georgiadis A, et al. Correction: Development of an optimized AAV2\/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65. Gene Ther. 2018;25(6):450.","journal-title":"Gene Ther"},{"issue":"12","key":"453_CR121","doi-asserted-by":"crossref","first-page":"a023754","DOI":"10.1101\/cshperspect.a023754","volume":"8","author":"T Gaj","year":"2016","unstructured":"Gaj T, et al. Genome-editing technologies: principles and applications. Cold Spring Harbor Perspect Biol. 2016;8(12):a023754.","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"453_CR122","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/jmedgenet-2019-106473","volume":"57","author":"D Benati","year":"2020","unstructured":"Benati D, et al. Gene editing prospects for treating inherited retinal diseases. J Med Genet. 2020;57:437\u201344.","journal-title":"J Med Genet"},{"key":"453_CR123","doi-asserted-by":"crossref","unstructured":"First CRISPR therapy dosed. Nat Biotechnol. 2020;38(4):382.","DOI":"10.1038\/s41587-020-0493-4"},{"issue":"18","key":"453_CR124","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","volume":"99","author":"GP Gao","year":"2002","unstructured":"Gao GP, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99(18):11854\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"453_CR125","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ymthe.2005.05.016","volume":"12","author":"TJ Conlon","year":"2005","unstructured":"Conlon TJ, et al. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. Mol Ther. 2005;12(5):867\u201375.","journal-title":"Mol Ther"},{"issue":"4","key":"453_CR126","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jgm.686","volume":"7","author":"JP Louboutin","year":"2005","unstructured":"Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med. 2005;7(4):442\u201351.","journal-title":"J Gene Med"},{"issue":"6","key":"453_CR127","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.gt.3303074","volume":"15","author":"M Natkunarajah","year":"2008","unstructured":"Natkunarajah M, et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2\/8. Gene Ther. 2008;15(6):463\u20137.","journal-title":"Gene Ther"},{"issue":"20","key":"453_CR128","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.1128\/JVI.01327-07","volume":"81","author":"M Allocca","year":"2007","unstructured":"Allocca M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol. 2007;81(20):11372\u201380.","journal-title":"J Virol"},{"issue":"3","key":"453_CR129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic J, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26(3):354\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"453_CR130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/hum.2015.035","volume":"26","author":"WT Deng","year":"2015","unstructured":"Deng WT, et al. Stability and safety of an AAV vector for treating RPGR-ORF15 X-linked retinitis pigmentosa. Hum Gene Ther. 2015;26(9):593\u2013602.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"453_CR131","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm1596","volume":"13","author":"JJ Alexander","year":"2007","unstructured":"Alexander JJ, et al. Restoration of cone vision in a mouse model of achromatopsia. Nat Med. 2007;13(6):685\u20137.","journal-title":"Nat Med"},{"key":"453_CR132","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/978-1-4419-1399-9_73","volume":"664","author":"JJ Pang","year":"2010","unstructured":"Pang JJ, et al. Achromatopsia as a potential candidate for gene therapy. Adv Exp Med Biol. 2010;664:639\u201346.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"453_CR133","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/mt.2010.149","volume":"18","author":"S Michalakis","year":"2010","unstructured":"Michalakis S, et al. Restoration of cone vision in the CNGA3-\/- mouse model of congenital complete lack of cone photoreceptor function. Mol Ther. 2010;18(12):2057\u201363.","journal-title":"Mol Ther"},{"issue":"13","key":"453_CR134","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/hmg\/ddq136","volume":"19","author":"AM Komaromy","year":"2010","unstructured":"Komaromy AM, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010;19(13):2581\u201393.","journal-title":"Hum Mol Genet"},{"issue":"16","key":"453_CR135","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1093\/hmg\/ddr218","volume":"20","author":"LS Carvalho","year":"2011","unstructured":"Carvalho LS, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet. 2011;20(16):3161\u201375.","journal-title":"Hum Mol Genet"},{"key":"453_CR136","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-4614-0631-0_25","volume":"723","author":"S Michalakis","year":"2012","unstructured":"Michalakis S, et al. Gene therapy restores missing cone-mediated vision in the CNGA3-\/- mouse model of achromatopsia. Adv Exp Med Biol. 2012;723:183\u20139.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"453_CR137","doi-asserted-by":"crossref","first-page":"e35250","DOI":"10.1371\/journal.pone.0035250","volume":"7","author":"JJ Pang","year":"2012","unstructured":"Pang JJ, et al. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One. 2012;7(4):e35250.","journal-title":"PLoS One"},{"issue":"10","key":"453_CR138","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.ophtha.2009.03.053","volume":"116","author":"AA Thiadens","year":"2009","unstructured":"Thiadens AA, et al. Genetic etiology and clinical consequences of complete and incomplete achromatopsia. Ophthalmology. 2009;116(10):1984\u20139.","journal-title":"Ophthalmology"},{"key":"453_CR139","doi-asserted-by":"crossref","unstructured":"Fischer MD et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial. JAMA Ophthalmol. 2020.","DOI":"10.1001\/jamaophthalmol.2020.1032"},{"issue":"5","key":"453_CR140","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/hum.2015.142","volume":"27","author":"RA Bush","year":"2016","unstructured":"Bush RA, et al. Preclinical dose-escalation study of intravitreal AAV-RS1 gene therapy in a mouse model of X-linked retinoschisis: dose-dependent expression and improved retinal structure and function. Hum Gene Ther. 2016;27(5):376\u201389.","journal-title":"Hum Gene Ther"},{"issue":"9","key":"453_CR141","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","volume":"26","author":"C Cukras","year":"2018","unstructured":"Cukras C, et al. Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery. Mol Ther. 2018;26(9):2282\u201394.","journal-title":"Mol Ther"},{"issue":"4","key":"453_CR142","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/ceo.13416","volume":"47","author":"CA Ramlogan-Steel","year":"2019","unstructured":"Ramlogan-Steel CA, et al. Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: trials, future directions and safety considerations. Clin Exp Ophthalmol. 2019;47(4):521\u201336.","journal-title":"Clin Exp Ophthalmol"},{"key":"453_CR143","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2018.04.012","volume":"192","author":"TJ Wubben","year":"2018","unstructured":"Wubben TJ, et al. Retinal neuroprotection: overcoming the translational roadblocks. Am J Ophthalmol. 2018;192:15\u201322.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"453_CR144","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/ICU.0000000000000558","volume":"30","author":"TJ Wubben","year":"2019","unstructured":"Wubben TJ, Zacks DN, Besirli CG. Retinal neuroprotection: current strategies and future directions. Curr Opin Ophthalmol. 2019;30(3):199\u2013205.","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"453_CR145","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1167\/iovs.16-19873","volume":"58","author":"BJ Yungher","year":"2017","unstructured":"Yungher BJ, Ribeiro M, Park KK. Regenerative responses and axon pathfinding of retinal ganglion cells in chronically injured mice. Investig Ophthalmol Vis Sci. 2017;58(3):1743\u201350.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"453_CR146","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1089\/hum.2017.069","volume":"29","author":"A Osborne","year":"2018","unstructured":"Osborne A, et al. Design of a novel gene therapy construct to achieve sustained brain-derived neurotrophic factor signaling in neurons. Hum Gene Ther. 2018;29(7):828\u201341.","journal-title":"Hum Gene Ther"},{"key":"453_CR147","doi-asserted-by":"crossref","first-page":"113167","DOI":"10.1016\/j.expneurol.2019.113167","volume":"326","author":"W Chiha","year":"2020","unstructured":"Chiha W, et al. Intravitreal application of AAV-BDNF or mutant AAV-CRMP2 protects retinal ganglion cells and stabilizes axons and myelin after partial optic nerve injury. Exp Neurol. 2020;326:113167.","journal-title":"Exp Neurol"},{"issue":"1","key":"453_CR148","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1038\/s41467-020-17821-1","volume":"11","author":"M Zaninello","year":"2020","unstructured":"Zaninello M, et al. Inhibition of autophagy curtails visual loss in a model of autosomal dominant optic atrophy. Nat Commun. 2020;11(1):4029.","journal-title":"Nat Commun"},{"issue":"368","key":"453_CR149","doi-asserted-by":"crossref","first-page":"368rv6","DOI":"10.1126\/scitranslmed.aaf2838","volume":"8","author":"HP Scholl","year":"2016","unstructured":"Scholl HP, et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8(368):368rv6.","journal-title":"Sci Transl Med"},{"key":"453_CR150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omtm.2020.05.009","volume":"18","author":"Q Lu","year":"2020","unstructured":"Lu Q, et al. Comparison of AAV-mediated optogenetic vision restoration between retinal ganglion cell expression and ON bipolar cell targeting. Mol Ther Methods Clin Dev. 2020;18:15\u201323.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3 Suppl","key":"453_CR151","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ajo.2004.04.058","volume":"138","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004;138(3 Suppl):S19\u201331.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"453_CR152","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3892\/etm.2020.8767","volume":"20","author":"C Ling","year":"2020","unstructured":"Ling C, et al. Updates on the molecular genetics of primary congenital glaucoma (Review). Exp Ther Med. 2020;20(2):968\u201377.","journal-title":"Exp Ther Med"},{"key":"453_CR153","doi-asserted-by":"crossref","first-page":"107893","DOI":"10.1016\/j.exer.2019.107893","volume":"190","author":"AC Gauthier","year":"2020","unstructured":"Gauthier AC. Childhood glaucoma genes and phenotypes: Focus on FOXC1 mutations causing anterior segment dysgenesis and hearing loss. Exp Eye Res. 2020;190:107893.","journal-title":"Exp Eye Res"},{"key":"453_CR154","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-vision-102016-061422","volume":"3","author":"M Almasieh","year":"2017","unstructured":"Almasieh M, Levin LA. Neuroprotection in Glaucoma: Animal Models and Clinical Trials. Annu Rev Vis Sci. 2017;3:91\u2013120.","journal-title":"Annu Rev Vis Sci"},{"issue":"10","key":"453_CR155","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1167\/iovs.02-1332","volume":"44","author":"KR Martin","year":"2003","unstructured":"Martin KR, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44(10):4357\u201365.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"453_CR156","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1167\/iovs.11-8484","volume":"53","author":"R Ren","year":"2012","unstructured":"Ren R, et al. Long-term rescue of rat retinal ganglion cells and visual function by AAV-mediated BDNF expression after acute elevation of intraocular pressure. Invest Ophthalmol Vis Sci. 2012;53(2):1003\u201311.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"453_CR157","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1167\/iovs.08-3013","volume":"50","author":"ME Pease","year":"2009","unstructured":"Pease ME, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009;50(5):2194\u2013200.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"453_CR158","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41419-018-1041-8","volume":"9","author":"A Osborne","year":"2018","unstructured":"Osborne A, et al. Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor\/tropomyosin-related kinase receptor-B signaling. Cell Death Dis. 2018;9(10):1007.","journal-title":"Cell Death Dis"},{"issue":"18","key":"453_CR159","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/sj.gt.3302791","volume":"13","author":"SG Leaver","year":"2006","unstructured":"Leaver SG, et al. AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells. Gene Ther. 2006;13(18):1328\u201341.","journal-title":"Gene Ther"},{"key":"453_CR160","doi-asserted-by":"crossref","unstructured":"Kimura A et al. Neuroprotection, growth factors and BDNF-TrkB signalling in retinal degeneration. Int J Mol Sci. 2016;17(9).","DOI":"10.3390\/ijms17091584"},{"key":"453_CR161","first-page":"1048","volume":"22","author":"NR Phatak","year":"2016","unstructured":"Phatak NR, Stankowska DL, Krishnamoorthy RR. Bcl-2, Bcl-xL, and p-AKT are involved in neuroprotective effects of transcription factor Brn3b in an ocular hypertension rat model of glaucoma. Mol Vis. 2016;22:1048\u201361.","journal-title":"Mol Vis"},{"key":"453_CR162","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1006\/mthe.2002.0608","volume":"5","author":"SJ McKinnon","year":"2002","unstructured":"McKinnon SJ, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5:780\u20137.","journal-title":"Mol Ther"},{"key":"453_CR163","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.omtm.2020.04.014","volume":"17","author":"J Tan","year":"2020","unstructured":"Tan J, et al. scAAV2-mediated C3 transferase gene therapy in a rat model with retinal ischemia\/reperfusion injuries. Mol Ther Methods Clin Dev. 2020;17:894\u2013903.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"453_CR164","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1167\/iovs.17-22972","volume":"59","author":"DS McDougald","year":"2018","unstructured":"McDougald DS, et al. SIRT1 and NRF2 gene transfer mediate distinct neuroprotective effects upon retinal ganglion cell survival and function in experimental optic neuritis. Investig Ophthalmol Vis Sci. 2018;59(3):1212\u201320.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"Pt 2","key":"453_CR165","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/brain\/aws100","volume":"135","author":"S Petratos","year":"2012","unstructured":"Petratos S, et al. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012;135(Pt 2):1794\u2013818.","journal-title":"Brain"},{"issue":"28","key":"453_CR166","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1523\/JNEUROSCI.1760-18.2019","volume":"39","author":"JY Lee","year":"2019","unstructured":"Lee JY, et al. Limiting neuronal nogo receptor signaling during experimental autoimmune encephalomyelitis preserves axonal transport and abrogates inflammatory demyelination. J Neurosci. 2019;39(28):5562\u201380.","journal-title":"J Neurosci"},{"issue":"8","key":"453_CR167","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1167\/iovs.13-12219","volume":"54","author":"B Fortune","year":"2013","unstructured":"Fortune B, et al. Onset and progression of peripapillary retinal nerve fiber layer (RNFL) retardance changes occur earlier than RNFL thickness changes in experimental glaucoma. Investig Ophthalmol Vis Sci. 2013;54(8):5653\u201361.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"453_CR168","first-page":"764","volume":"41","author":"ME Pease","year":"2000","unstructured":"Pease ME, et al. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Investig Ophthalmol Vis Sci. 2000;41(3):764\u201374.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"453_CR169","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/mus.26001","volume":"57","author":"N Goyal","year":"2018","unstructured":"Goyal N, Narayanaswami P. Making sense of antisense oligonucleotides: a narrative review. Muscle Nerve. 2018;57(3):356\u201370.","journal-title":"Muscle Nerve"},{"issue":"7","key":"453_CR170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/hum.2013.234","volume":"25","author":"P Disterer","year":"2014","unstructured":"Disterer P, et al. Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther. 2014;25(7):587\u201398.","journal-title":"Hum Gene Ther"},{"issue":"5\u20136","key":"453_CR171","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JH Chan","year":"2006","unstructured":"Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol. 2006;33(5\u20136):533\u201340.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"453_CR172","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tig.2011.02.004","volume":"27","author":"SM Hammond","year":"2011","unstructured":"Hammond SM, Wood MJ. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 2011;27(5):196\u2013205.","journal-title":"Trends Genet"},{"issue":"19","key":"453_CR173","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","volume":"268","author":"BP Monia","year":"1993","unstructured":"Monia BP, et al. Evaluation of 2\u2032-modified oligonucleotides containing 2\u2032-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993;268(19):14514\u201322.","journal-title":"J Biol Chem"},{"key":"453_CR174","doi-asserted-by":"crossref","unstructured":"Sardone V et al. Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules. 2017;22(4).","DOI":"10.3390\/molecules22040563"},{"issue":"9","key":"453_CR175","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1517\/13543784.6.9.1157","volume":"6","author":"J Temsamani","year":"1997","unstructured":"Temsamani J, Pari GS, Guinot P. Antisense approach for the treatment of cytomegalovirus infection. Expert Opin Investig Drugs. 1997;6(9):1157\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"453_CR176","doi-asserted-by":"crossref","unstructured":"Vazquez-Dominguez I, Garanto A, Collin RWJ. Molecular therapies for inherited retinal diseases-current standing, opportunities and challenges. Genes (Basel). 2019;10(9).","DOI":"10.3390\/genes10090654"},{"key":"453_CR177","doi-asserted-by":"crossref","unstructured":"Garanto A et al. Antisense oligonucleotide screening to optimize the rescue of the splicing defect caused by the recurrent deep-intronic ABCA4 variant c.4539+2001G>A in Stargardt disease. Genes (Basel). 2019;10(6).","DOI":"10.3390\/genes10060452"},{"key":"453_CR178","doi-asserted-by":"crossref","unstructured":"Naessens S et al. Antisense oligonucleotide-based downregulation of the G56R pathogenic variant causing NR2E3-associated autosomal dominant retinitis pigmentosa. Genes (Basel). 2019;10(5).","DOI":"10.3390\/genes10050363"},{"key":"453_CR179","doi-asserted-by":"crossref","unstructured":"Niu C et al. Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Sci Transl Med. 2018;10(465).","DOI":"10.1126\/scitranslmed.aap8677"},{"key":"453_CR180","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.omtn.2018.07.010","volume":"12","author":"K Dulla","year":"2018","unstructured":"Dulla K, et al. Splice-modulating Oligonucleotide QR-110 restores CEP290 mRNA and function in human c2991+1655A>G LCA10 models. Mol Ther Nucleic Acids. 2018;12:730\u201340.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"453_CR181","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1038\/mtna.2016.89","volume":"5","author":"RW Slijkerman","year":"2016","unstructured":"Slijkerman RW, et al. Antisense oligonucleotide-based splice correction for USH2A-associated retinal degeneration caused by a frequent deep-intronic mutation. Mol Ther Nucleic Acids. 2016;5(10):e381.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"453_CR182","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","volume":"116","author":"W Xiong","year":"2019","unstructured":"Xiong W, et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc Natl Acad Sci USA. 2019;116(12):5785\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"453_CR183","doi-asserted-by":"crossref","first-page":"107453","DOI":"10.1016\/j.pharmthera.2019.107453","volume":"207","author":"NF Nidetz","year":"2020","unstructured":"Nidetz NF, et al. Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery. Pharmacol Ther. 2020;207:107453.","journal-title":"Pharmacol Ther"},{"key":"453_CR184","unstructured":"Retnet: Genes and mapped loci causing retinal diseases. https:\/\/sph.uth.edu\/retnet\/disease.htm. Accessed 21 Oct 2020."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-020-00453-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T18:10:53Z","timestamp":1618164653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-020-00453-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":184,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00453-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"2 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by the Lions Eye Institute (LEI), Usher 1F Collaborative and Genetics Cures Australia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that this review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"LSC wrote the first draft of the manuscript; ARH, PFC and HB wrote sections of the manuscript and drafted the tables and all authors contributed to manuscript revision and approval of the submitted version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N\/A.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"N\/A.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}